We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hematology Analyzer Evaluated for Cerebrospinal Fluid Testing

By LabMedica International staff writers
Posted on 04 Apr 2012
One of newest generation hybrid hematology analyzer is equipped with an improved body fluid analysis mode that is suitable for cerebrospinal fluid (CSF) analysis. More...


The cellular components of CSF have conventionally been enumerated microscopically by using a hemocytometer-counting chamber, but this is labor intensive and time consuming, and maybe replaced by a hematology autoanalyzer.

Laboratory scientists at the Medical University of Vienna (Austria) analyzed a total of 425 consecutive CSF samples sent to the Department of Laboratory Medicine for routine testing. Microscopic cell counts were performed by biomedical technicians using a Fuchs-Rosenthal counting chamber after samples were stained with methyl violet acetic acid.

CSF samples were measured for white blood cells (WBCs) using the body fluid mode of the XE-5000 Hematology Analyzer. By combining fluorescent dye binding and semiconductor laser technology, the XE-5000 (Sysmex Corporation; Kobe, Japan) differentiates between WBCs that are mononuclear cells (MN), including lymphocytes and monocytes and those that are polymorphonuclear cells (PMN), including all types of granulocytes.

For total WBC counts, the proportions of samples correctly classified by the XE-5000 from different groups were: 88% for 0 to 5 WBC/µL in 330 samples; 47% for 6 to10 WBC/µL in 36 samples; 72% for 11 to 50 WBC/µL in 39 samples; 93% for 51 to 200 WBC/µL in15 samples; and 100% for cell counts above 200 WBC/µL. After the two lowest count categories were combined into one range of 0 to10 WBC/µL, matches increased to 95%. For PMN counts in the 0% to 25% group, 37% of samples were misclassified by the XE-5000. Conversely, for samples with microscopic PMN counts of more than 25%, there was a trend toward underestimation by the XE-5000. Mismatches were most pronounced in samples with fewer than 10 WBC/µL.

The authors concluded that based on the results of their study, they felt confident in recommending the XE-5000 as a reliable WBC counter for CSF, even for samples with low WBC counts, which comprise most laboratory admissions. It was previously recommended that all samples with cell counts of less than 5 and more than 20 WBC/µL on the XE-5000 be manually recounted, but the authors propose selecting samples for microscopic rework based on their DIFF channel scattergrams rather than predefined WBC count results. However, it cannot be recommended as a suitable alternative for manual differential cytological workup. The study was published in the February 2012 edition of the journal Archives of Pathology & Laboratory Medicine.

Related Links:

Medical University of Vienna
Sysmex Corporation




New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Portable Electronic Pipette
Mini 96
Gel Cards
DG Gel Cards
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.